Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Trulicity ®
Indication: Treatment of type 2 diabetes mellitus in adults to improve glycaemic control
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No


The GLP‑1 agonist Dulaglutide is indicated in adults with type 2 diabetes mellitus to improve glycaemic control.
NICE Guideline 28 only recommends the prescribing of GLP‑1 agonists in the add-on therapy setting; therefore dulaglutide was reviewed only in the add-on therapy setting.
Dulaglutide is a drug appropriate for initiation and ongoing prescribing in both primary and secondary care when prescribed in line with NICE Guideline 28 after second intensification of therapy fails to achieve targets combined with metformin and a sulfonylurea or combined with insulin at second intensification of treatment in patients who cannot take metformin.
Dulaglutide may only be continued if the person has a beneficial metabolic response, as defined in NICE Guideline 28.
The LMMG recommends dulaglutide as a 1st line GLP‑1 agonist.


LMMG recommendation: Green
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care

Supporting documents:

New Medicine Recommendation - Albiglutide And Dulaglutide (1.1 MiB)

Algorithm For Antihyperglycaemic Therapy In Adults With Type II (Version 1.4) (585.4 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG